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In a recent issue of Arthritis Research & Th  erapy, van de 
Geijn and colleagues [1] analyse the role of immuno-
globulin G (IgG) galactosylation as a disease-remitting 
factor in pregnant patients with rheumatoid arthritis 
(RA). Th  e pregnancy-induced improvement of RA has 
intrigued researchers since the time of Philipp Hench, 
who in searching for the remission-inducing factor 
discovered cortisone [2]. Unfortunately, neither the 
corticosteroids nor other circulating factors, such as sex 
steroid hormones or α-2 pregnancy-associated globulin, 
proved to be the crucial players that could explain 
remission of RA in pregnant patients [3-5]. Th  erefore,  the 
search for a factor or a combination of factors able to 
substantially mitigate symptoms of RA continued.
Changes in the percentage of IgG molecules lacking the 
terminal galactose units in the oligosaccharide chains 
attached to CH2 regions have been investigated as a 
possible explanation for amelioration of RA during 
pregnancy. Th  e percentage of agalactosyl IgG (Gal-0) 
varies as a function of age in normal healthy individuals; 
however, in patients with RA, Gal-0 levels exceed age-
related normal values [6]. Two studies including 8 and 23 
RA patients during pregnancy and postpartum found a 
correlation between changes in disease activity and 
changes in Gal-0 [7,8]. However, no signiﬁ  cant diﬀ  erence 
was seen in the galactosylation levels between the 11 
patients that experienced remission and the 12 patients 
with persistent active disease during pregnancy [8].
In their study, van de Geijn and colleagues [1] report on 
immunoglobulin galactosylation in 148 RA patients and 
32 healthy controls during and after pregnancy. Applying 
the European League Against Rheumatism response 
criteria, the authors were able to identify a pregnancy 
responder group as well as a non-responder group of RA 
patients. As shown previously [7], IgG galactosylation 
increased during pregnancy and decreased postpartum 
in healthy controls as well as in RA patients, showing this 
to be a pregnancy related phenomenon. High galacto-
sylation levels were associated with low disease activity of 
RA and vice versa. Interestingly, increased galactosylation 
levels during pregnancy were more pronounced in the RA 
responder group and resembled those of healthy women.
Does this study provide a ﬁ   nal answer for the 
spontaneous improvement or remission occurring in 
most pregnant RA patients? Changes in disease activity 
and changes in circulating proteins during and after 
pregnancy could be merely coincidental. Th  e major 
problem of previous investigations has been the very 
limited number of pregnant RA patients studied and the 
inability to compare groups of remitting and non-
remitting RA patients. A true candidate should either 
have a direct or inverse correlation with RA disease 
activity. Furthermore, levels should be signiﬁ  cantly 
diﬀ  erent in patients that improve and those that do not. 
In the study of van de Geijn and colleagues [1], the levels 
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During pregnancy, most patients with rheumatoid 
arthritis (RA) experience spontaneous improvement of 
their disease activity. Among the soluble candidates 
that have been investigated in search for the most 
relevant disease-remitting factor are the galactosylation 
levels of immunoglobulin G (IgG). In RA, a higher 
percentage of IgG lacking the terminal galactose 
residues, thought to play a pro-infl  ammatory role, is 
found. During pregnancy, however, IgG galactosylation 
levels increase and correlate with improved disease 
activity. The question remains whether the increase 
in IgG galactosylation during pregnancy is a mere 
epiphenomenon or a true remission-inducing factor.
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improved and those that did not were signiﬁ  cantly 
diﬀ  erent. Th   us far, the study has conﬁ  rmed that levels of 
disease activity and levels of IgG galactosylation are 
inversely correlated, and this is independent of 
pregnancy. Changes in disease activity and levels of IgG 
galactosylation occurred simultaneously, which leaves 
the question open whether the relationship is causal or 
an epiphenomenon.
Obviously, IgG galactosylation is a pregnancy-related 
phenomenon most abundant in healthy pregnant women 
and possibly necessary to protect the fetus against anti-
paternal antibodies. Whether it can modify autoimmune 
disease remains an open question. Elevated agalactosyl 
IgG levels are also present in Crohn’s disease patients [9]. 
However, these patients experience either no or only mild 
improvement of their disease during pregnancy [10]. 
Th   us, the pregnancy-related increase of IgG galacto  sy  la-
tion does not seem to play a relevant role in the activity 
of Crohn’s disease.
Th   e role of IL-6 in the modiﬁ  cation of IgG galacto  sy  la-
tion is of interest. Low concentrations of IL-6 were shown 
to increase IgG galactosylation via modulation of glyco-
syl  transferase activity [11]. However, high levels of IL-6 
decreased the glycosyltransferase activity. Th  erefore,  IL-6 
of placental origin could induce increased IgG 
galactosylation levels during pregnancy whereas elevated 
IL-6 levels of active RA patients could account for lower 
IgG galactosylation rates.
Th  e ﬁ   nal proof for a causal relationship between 
pregnancy-induced improvement of RA and IgG 
galactosylation levels is still lacking. Other factors 
contributing to maternal/fetal tolerance, such as Th  2 
cytokines, HLA-G/HLA-E, fetal antigens, inhibitory co-
stimulatory molecules, complement regulators, regula  tory 
T cells, and indoleamine 2,3-dioxygenase-producing 
dendritic cells, could be involved, acting further upstream.
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